aTyr Pharma Inc.

228 articles with aTyr Pharma Inc.

• aTyr Pharma Appoints Industry Veteran In Novel Biology Biologics, David J. King, Phd, As Senior Vice President, Research

  9/22/2016

• aTyr Pharma Announces Second Quarter 2016 Operating Results

  8/11/2016

• aTyr Pharma To Present At Jefferies 2016 Healthcare Conference

  6/3/2016

• aTyr Pharma Announces First Quarter 2016 Operating Results

  5/12/2016

• aTyr Pharma Appoints Grove Matsuoka As Senior Vice President, Product Programs And Planning

  5/5/2016

• aTyr Pharma To Present At Upcoming May Investor Conferences

  4/29/2016

• aTyr Pharma To Present At 15th Annual Needham & Company Healthcare Conference

  4/6/2016

• aTyr Pharma Appoints Sanjay Shukla, MD, MS, As Chief Medical Officer

  3/31/2016

• aTyr Pharma Announces Fourth Quarter 2015 Operating Results

  3/31/2016

• aTyr Pharma Announces Encouraging Phase 1b/2 Results For Resolaris In Its First Rare Myopathy Trial

  3/31/2016

• aTyr Pharma Provides Corporate Update And Outlook For 2016

  1/11/2016

• aTyr Pharma To Present At 34th Annual J.P. Morgan Healthcare Conference

  1/7/2016

• aTyr Pharma Appoints Sanuj Ravindran, M.D., As Chief Business Officer

  1/7/2016

• aTyr Pharma Added To NASDAQ Biotechnology Index

  12/16/2015

• aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine For GMP Process Development And For Potential Treatment Of Severe Lung Diseases

  11/11/2015

• aTyr Pharma Announces Third Quarter 2015 Operating Results

  11/11/2015

• aTyr Pharma To Host Breakout Session At The 6th Annual World Orphan Drug Congress

  11/10/2015

• aTyr Pharma Initiates Phase 1b/2 Clinical Trial In Patients With Early Onset FSHD

  11/9/2015

• Nature Release: Publication In aTyr Pharma Demonstrates Physiocrine Genetic Mutation Disrupts A Key Signaling Pathway In Neuronal Biology

  11/4/2015

• aTyr Pharma To Present At 24th Annual Credit Suisse Healthcare Conference

  11/3/2015